glp 1 and memory loss 🧐Will GLP-1RA drugs be the future of altzeimers treatement? 🧠There are multiple studies underway assessing the effectiveness of glp-1 class of medications in prevention and/or delay of dementia 🧠Alzheimer's makes up 60%-80% Glucagon-like peptide-1 (GLP-1) receptor agonists

Recently, the GLP-1 RA semaglutide was reported to reduce cardiovascular events in ASCVD patients with overweight or obesity even in the absence of diabetes mellitus

As such, there is growing interest in repurposing medications with novel mechanisms of action

It just shows you the level of desperation that people have and the level of unmet need that we have when it comes to treating obesity effectively."

The program runs July 1, 2026 through December 31, 2027.

Zooming out, the obesity market is now clearly split across modalities: Novo Nordisk still anchors the peptide side with semaglutide, while oral small molecules are accelerating (orforglipron, elecoglipron and Roches Carmot deal)